Van ECK Associates Corp Decreases Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Van ECK Associates Corp decreased its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 18.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 49,379 shares of the specialty pharmaceutical company’s stock after selling 10,832 shares during the quarter. Van ECK Associates Corp’s holdings in Jazz Pharmaceuticals were worth $6,081,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in JAZZ. CWA Asset Management Group LLC acquired a new position in shares of Jazz Pharmaceuticals in the third quarter valued at approximately $3,197,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Jazz Pharmaceuticals by 135.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock valued at $19,394,000 after purchasing an additional 100,112 shares during the period. Centre Asset Management LLC acquired a new position in shares of Jazz Pharmaceuticals in the fourth quarter valued at approximately $9,335,000. Moloney Securities Asset Management LLC acquired a new position in shares of Jazz Pharmaceuticals in the fourth quarter valued at approximately $464,000. Finally, Pacer Advisors Inc. increased its holdings in shares of Jazz Pharmaceuticals by 15.3% in the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock valued at $233,892,000 after purchasing an additional 278,465 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Morgan Stanley raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $140.00 to $175.00 in a report on Thursday, December 12th. Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $130.00 to $170.00 in a report on Thursday, February 13th. Robert W. Baird upped their price objective on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a report on Monday, November 18th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $179.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. Finally, TD Cowen dropped their price objective on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. One research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $180.33.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total value of $185,145.00. Following the sale, the chief executive officer now owns 425,525 shares of the company’s stock, valued at $52,522,550.75. This trade represents a 0.35 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In the last quarter, insiders have sold 5,053 shares of company stock valued at $617,442. 4.20% of the stock is owned by company insiders.

Jazz Pharmaceuticals Stock Down 2.1 %

Shares of JAZZ opened at $133.96 on Tuesday. The firm has a market capitalization of $8.10 billion, a price-to-earnings ratio of 18.87, a PEG ratio of 0.92 and a beta of 0.56. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The business’s fifty day moving average price is $123.73 and its two-hundred day moving average price is $117.41. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $138.27.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.